Of 1,272 patients ( FREEDOMS ITT population ) , 1,033 were eligible , and 920 enrolled in the extension study ( continuous-fingolimod : 0.5 mg [ n = 331 ] , 1.25 mg [ n = 289 ] ; placebo-fingolimod : 0.5 mg [ n = 155 ] , 1.25 mg [ n = 145 ] ) ; 916 formed the extension ITT population ( n = 330 ; n = 287 ; n = 154 ; n = 145 ) and 773 ( 84 % ) completed .